All In Biotech

Drug Trial Radar · NCT05445778

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab

Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

520

Actual

Start

Mar 15, 2023

Primary completion

Apr 2027

Study completion May 2032

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
GOG Foundation
First posted
Jul 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Conditions

  • Ovarian Cancer
  • Peritoneal Cancer
  • Fallopian Tube Cancer

Interventions

  • Mirvetuximab soravtansine plus BevacizumabDrug

    Participants will receive MIRV 6.0 mg/kg adjusted ideal body weight (AIBW) plus Bevacizumab 15mg/kg every 3 weeks

  • BevacizumabDrug

    Participants will receive Bevacizumab 15mg/kg every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess Progression-free survival (PFS)Time frame: Up to 4 years

Locations

264 sites in 22 countries. Site status is shown where the registry gives one.

  • Usa Mitchell Cancer Institute /ID# 269661

    Mobile, Alabama

  • Honorhealth Virginia G. Piper Cancer Care Network - Biltmore /ID# 269987

    Phoenix, Arizona

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 269573

    Irvine, California

  • Moores Cancer Center at UC San Diego /ID# 269564

    La Jolla, California

  • Kaiser Permanente - Los Angeles Medical Center /ID# 269541

    Los Angeles, California

  • University Of California Irvine Medical Center /ID# 269572

    Orange, California

  • Stanford Women'S Cancer Center /ID# 269552

    Palo Alto, California

  • Kaiser Permanente - Riverside Medical Center /ID# 269539

    Riverside, California

  • Kaiser Permanente Zion Medical Center /ID# 269537

    San Diego, California

  • Kaiser Permanente - San Diego Medical Center /ID# 269540

    San Diego, California

  • Kaiser Permanente - San Marcos Medical Offices /ID# 269542

    San Marcos, California

  • Olive View-Ucla Medical Center /ID# 269584

    Sylmar, California

  • John Muir Health - Walnut Creek Medical Center /ID# 269575

    Walnut Creek, California

  • Broward General Medical Center /ID# 269577

    Fort Lauderdale, Florida

  • Regional Cancer Center /ID# 269558

    Fort Myers, Florida

  • Baptist Md Anderson Cancer Center - Jacksonville - Palm Avenue /ID# 269560

    Jacksonville, Florida

  • Mount Sinai Medical Center /ID# 269582

    Miami, Florida

  • Sarasota Memorial Hospital /ID# 269526

    Sarasota, Florida

  • Northside Hospital /ID# 269660

    Atlanta, Georgia

  • Rush University Medical Center /ID# 269583

    Chicago, Illinois

  • University of Chicago Medical Center /ID# 269546

    Chicago, Illinois

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center /ID# 269110

    Indianapolis, Indiana

  • St. Vincent Indianapolis Hospital /ID# 269107

    Indianapolis, Indiana

  • University of Iowa /ID# 269566

    Iowa City, Iowa

  • The University of Kansas Cancer Center - Westwood /ID# 269106

    Westwood, Kansas

  • Baptist Health Lexington /ID# 269568

    Lexington, Kentucky

  • University of Kentucky Chandler Medical Center. /ID# 269536

    Lexington, Kentucky

  • Louisiana State University Health Sciences Center - New Orleans /ID# 269559

    New Orleans, Louisiana

  • Ochsner Medical Center - Jefferson Highway /ID# 269530

    New Orleans, Louisiana

  • Maine Medical Center - Scarborough Campus /ID# 269555

    Scarborough, Maine

  • Johns Hopkins Hospital /ID# 269579

    Baltimore, Maryland

  • Sinai Hospital Of Baltimore /ID# 269567

    Manchester, Maryland

  • GBMC Cancer Center /ID# 269561

    Towson, Maryland

  • Tufts Medical Center /ID# 269547

    Boston, Massachusetts

  • Baystate Medical Center /ID# 269544

    Springfield, Massachusetts

  • Corewell Health /ID# 269562

    Grand Rapids, Michigan

  • Minnesota Oncology - Coon Rapids Clinic /ID# 269550

    Coon Rapids, Minnesota

  • Nebraska Methodist Hospital /ID# 269580

    Omaha, Nebraska

  • The Center Of Hope /ID# 269528

    Reno, Nevada

  • Dartmouth-Hitchcock Medical Center /ID# 269576

    Lebanon, New Hampshire

Showing 40 of 264 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.